Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality ...

Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring ...

Adding artificial intelligence (AI) to legacy pharma supply chain systems requires auditable human intelligence to fix data ...

Pharmaceutical Executive spoke with Mark Talens, CCO of PAXAFE at LogiPharma 2026 in Boston. During the conversation., the executive discussed a variety of issues and updates on modern supply chains ...

Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.

Biswas has more than 25 years of leadership experience across life sciences and technology, with expertise in manufacturing, quality and compliance, and enterprise-scale digital transformation. His ...

Laboratory logistics form the foundation of clinical research by ensuring biological samples, investigational materials, and time-sensitive data move safely and seamlessly across sites. Marken UPS ...

Sponsors in North America and APAC with plans to enter the European marketplace must contend with Joint Clinical Assessment ...

How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.

Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value. Caribou Biosciences, Inc. announced that it is exploring ...

Pharmaceutical Executive spoke with Dr. Bo Liang, chief medical officer at CORXEL, about the trajectory of GLP-1s. Dr. Liang previously worked at Novo Nordisk, where he lead global clinical ...

CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits ...